NeuroMetrix, Inc.

  • Market Cap: Micro Cap
  • Industry: Medical Specialties
  • ISIN: US6412558800
USD
4.58
0.22 (5.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About NeuroMetrix, Inc. stock-summary
stock-summary
NeuroMetrix, Inc.
Medical Specialties
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Company Coordinates stock-summary
Company Details
1000 Winter St , WALTHAM MA : 02451-1436
stock-summary
Tel: 1 781 8909989
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.81%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Shai Gozani
Chairman of the Board, President, Chief Executive Officer, Secretary, Director
Dr. David Goodman
Independent Director
Ms. Nancy Katz
Independent Director
Mr. David Van Avermaete
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Dec 2024)
Net Profit:
-2 Million
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

408.36%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-54.54%

stock-summary
Price to Book

0.66